ClinicalTrials.gg
CompletedNCT00135005Updated Dec 8, 2020

Study of AMN107 With Imatinib in Gastrointestinal Stromal Tumors (GIST)

A Phase 1 interventional study of AMN107, STI571 in Gastrointestinal Stromal Tumors, sponsored by Novartis Pharmaceuticals. Completed at 5 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-08.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
59
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing nilotinib in Gastrointestinal Stromal Tumors — none open to participants now, none under way, none of them phase 3. nilotinib · Gastrointestinal Stromal Tumors.

Enrollment
5th of 14
59 · median 35
Started
2005
the only one that year
Phase 1
2 of 14
none open now
Registered
1st of 14
by date
Lead sponsor
12 of 14
Novartis Pharmaceuticals

Among the 14 studies testing nilotinib in Gastrointestinal Stromal Tumors, this one is the 5th largest by enrollment, is the only one that started in 2005, is one of 2 in phase 1, and was the 1st registered.

Gastrointestinal Stromal Tumors

343 studies on the registry are indexed under Gastrointestinal Stromal Tumors; 61 are open to participants now.

Browse Gastrointestinal Stromal Tumors studies →

Open to participants now

None of the 14 studies testing nilotinib in Gastrointestinal Stromal Tumors is open now. The open studies under Gastrointestinal Stromal Tumors, anywhere →

About nilotinib

nilotinib: first FDA approval 2007 (TASIGNA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 49 Gastrointestinal Stromal Tumors studies recruiting now, 38 (78%) set no upper age limit and 4 (8%) stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing nilotinib in Gastrointestinal Stromal Tumors as a file.
02

Study summary

This study is an open-label, multicenter, Phase I dose-escalation study of the combination of AMN107 and imatinib (STI571) in patients with imatinib-resistant GIST. This study is designed to determine the Phase II dose of AMN107 and imatinib when administered together in patients with imatinib-resistant GIST, and to characterize the safety, tolerability and pharmacokinetic (PK) profile of this combination.

03

Conditions studied

  • Gastrointestinal Stromal Tumors

Keywords

  • GIST
  • AMN107
  • Gastrointestinal Stromal Tumors
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with gastrointestinal stromal tumor (GIST).
  • Patients who have had disease progression during imatinib therapy with 800 mg.
  • Ability to understand and willingness to sign a written document.

Exclusion criteria

Exclusion Criteria:

  • Patients with prior or concomitant other than GIST with the exception of previous or concomitant basal cell skin cancer or previous cervical carcinoma in situ.
  • A history of impaired cardiac function or uncontrolled cardiovascular disease.
  • Severe and/or uncontrolled concurrent disease that could cause unacceptable safety risks such as impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of AMN107.
  • Currently taking certain medications that could affect an result.
  • Women who are pregnant or breast feeding.
  • Patients unwilling or unable to comply with the protocol.

NOTE: Additional inclusion and/ or exclusion criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
59 participants (actual)

Study arms

  • Experimental
    AMN107 + STI571

    Drug: AMN107, STI571

Interventions

06

What researchers measure

Primary outcomes

  1. To determine the MTD which will be the Phase II dose of AMN107 when given in combination with Imatinib. The MTD is defined to be the highest dose of AMN107 in combination with Imatinib given for at least 21 days in the first treatment cycle

    MTD is defined to be the highest dose of AMN in combination with imatinib given for at least 21 days in the first treatment cycle

    Time frame: From day 1 cycle 1 until at least six subjects have been treated at the recommended dose level and observed for at least 21 days

Secondary outcomes

  1. To characterize safety and tolerability of AMN107 in combination with Imatinib in GIST

    Time frame: From day 1 cycle to the study completion visit

  2. patients showing progression of disease on Imatinib. The patient will be followed-up for at least 4 cycles (28 days for one cycle)

    cycle = 28 days

    Time frame: up to 4 cycles after disease profression on imatinib

07

Study locations

5 sites
  • Novartis Investigative Site
    Boston, Massachusetts 02115, United States
  • Novartis Investigative Site
    Philadelphia, Pennsylvania 19111-2497, United States
  • Novartis Investigative Site
    Lyon Cedex, 69373, France
  • Novartis Investigative Site
    Berlin, 13125, Germany
  • Novartis Investigative Site
    Milano, MI 20133, Italy
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2005, a primary completion of Nov 2006 and a completion of Nov 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2005
First posted
Aug 25, 2005
Start
Aug 2005
Primary completionActual
Nov 2006
CompletionActual
Nov 2006
Last update
Dec 8, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 8, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00135005
Responsible party
Sponsor
First posted
Aug 25, 2005
Start date
Aug 2005
Primary completion
Nov 2006
Completion
Nov 2006
Last update
Dec 8, 2020

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nilotinib · Imatinib

Start the discussion